title: Scedosporium prolificans fungaemia in a patient with acute lymphoblastic leukaemia.
abstract: Aggressive chemotherapy and immunosuppressive treatment may prolong patients' life, but influence the risk of severe, life-threatening infections. Here, we report the case of a 21-year-old caucasian female who developed a disseminated infection of Scedosporium prolificans after allogenic stem cell transplantation performed for treatment of relapsed acute lymphoblastic leukaemia. The pathogen was isolated from the blood and identified on the basis of its macroscopic and microscopic morphological features. The empirical treatment with amphotericin B provided no improvement. However, introduction of intravenous voriconazole resulted in amelioration of fever. Unfortunately, the patient died due to progression of underlying disease and multiorgan failure. However, this case report indicates a possible relevance of voriconazole-based treatment regimens in invasive S. prolificans infections.
authors.affiliation: Department of Dermatology, Poznan University of Medical Sciences, Poland.
authors.forename: H
authors.initials: H
authors.lastname: Kubisiak-Rzepczyk
authors.forename: L
authors.initials: L
authors.lastname: Gil
authors.forename: A
authors.initials: A
authors.lastname: Zawirska
authors.forename: A
authors.initials: A
authors.lastname: Kubisiak-Michalska
authors.forename: A
authors.initials: A
authors.lastname: Mol
authors.forename: A
authors.initials: A
authors.lastname: Reich
authors.forename: M
authors.initials: M
authors.lastname: Komarnicki
authors.forename: Z
authors.initials: Z
authors.lastname: Adamski
mesh_terms: D064591:Allografts; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D057915:Drug Substitution; D017809:Fatal Outcome; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use; D016469:Fungemia / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology; D006086:Graft vs Host Disease / Q000188:drug therapy; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000188:drug therapy; D012008:Recurrence; D021681:Scedosporium / Q000302:isolation & purification*; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use; D065819:Voriconazole / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D014230:Triazoles; C101425:posaconazole; D000666:Amphotericin B; D015725:Fluconazole; D065819:Voriconazole
keywords: Acute leukaemia; Disseminated fungal infection; Immunocompromised patient; Immunodépression; Infection fongique disséminée; Leucémie aiguë; Scedosporium prolificans; Voriconazole